FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 04/2024”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the US Healthcare & Life Sciences sector.
As of the tip of April 2024 we recognized the next present VC developments in the US:
- Complete Healthcare & Life Sciences funding reached EUR 11,689m
- Biotech obtained 66% (together with 8% by way of the funding of Xaira Therapeutics) of the overall funding quantity (EUR 7,702m) with oncology being the main indication (28%)
- In April the Digital Remedy Improvement Firm Xaira Therapeutics secures the very best transaction quantity with EUR 930m, adopted by Metsera with EUR 322m and Cerevance with EUR 152m
- ARCH Enterprise Companions (United States) is essentially the most energetic investor (by deal quantity), adopted by RA Capital Administration (United States) and F-Prime Capital (United States)
To entry the total report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink.